key: cord-1047681-3g06zxmx authors: Nile, Shivraj Hariram; Nile, Arti; Qiu, Jiayin; Li, Lin; Jia, Xu; Kai, Guoyin title: COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons date: 2020-05-07 journal: Cytokine Growth Factor Rev DOI: 10.1016/j.cytogfr.2020.05.002 sha: bb631ab46d33369a92ab98db3aedc721221b7237 doc_id: 1047681 cord_uid: 3g06zxmx ABSTRACT The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into a major health hazard across the globe. The rapid escalation of the COVID-19 and the considerable associated illness leading to death has transformed it into a critical global public health issue. The current clinical investigation in patients with COVID-19 has showed strong upregulation of cytokine and interferon production after critical infection with SARS-CoV2- induced pneumonia. The current research suggests that few groups of patients with COVID-19 might have a cytokine storm syndrome. Thus, identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality. To date, no specific therapeutic drug or vaccine has been discovered to treat this COVID-19. Intensive research is in progress to identify a promising drug therapy. Hence, several options were proposed to control this fast-emerging pandemic, including antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs). the considerable associated illness leading to death has transformed it into a critical global public health issue. The current clinical investigation in patients with COVID-19 has showed strong upregulation of cytokine and interferon production after critical infection with SARS-CoV2-induced pneumonia. The current research suggests that few groups of patients with COVID-19 might have a cytokine storm syndrome. Thus, identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality. To date, no specific therapeutic drug or vaccine has been discovered to treat this COVID-19. Intensive research is in progress to identify a promising drug therapy. Hence, several options were proposed to control this fast-emerging pandemic, including antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs). Covid-19 pathogenesis COVID-19 caused by SARS-COV2 virus; a potentially fatal disease represents great global public health concern. This virus infects the lower respiratory tract and cause pneumonia in human, seems that the symptoms are milder than SARS and MERS [1] . As off now not much information about the mortality, pathobiology and cellular responses about this disease is known, a probable course of events can be postulated based on past studies with SARS-CoV. Based on the cells that are likely infected, J o u r n a l P r e -p r o o f SARS-CoV-2 infection can be roughly divided into three stages; I. Asymptomatic phase with or without detectable virus, II. Non-severe symptomatic with upper airway and conducting airway response and III. Hypoxia, ground glass infiltrates, and progression of acute respiratory distress syndrome (ARDS) with high viral load that correspond to different clinical stages of the disease (Fig 1) [2] . Coronaviruses genome encodes four major proteins spike (S), nucleocapsid (N), membrane (M), and envelope (E). The S protein helps viral entry in to target cell of the body. Research has shown that about 75 percent of the COVID-19 S genome is the same as the SARS-CoV genome. However, the amino acid residues needed for receptor binding are the same between these two viruses. This also suggests that the entry receptor, ACE-2, used by SARS-CoV is the same for SARS-CoV-2 as well [3] . The study in published in Lancet shows ARDS is the main death cause of COVID-19 causing common immunopathological event for SARS-CoV-2, SARS-CoV and MERS-CoV infections [4] . One of the main mechanisms for ARDS is the cytokine storm, the deadly uncontrolled systemic inflammatory response resulting from the release of large amounts of pro-inflammatory cytokines and chemokines by immune effector cells in SARS-CoV infection [5] . Significantly high blood levels of cytokines and chemokines were also noted in patients with COVID-19 infection that included IL1-β, IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1α, MIP1β, PDGFB, TNFα, and VEGFA. Some of the severe cases that were admitted to the intensive care unit showed high levels of pro-inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1α, and TNFα that are reasoned to J o u r n a l P r e -p r o o f promote disease severity [6] . The cytokine storm will trigger a violent attack by the immune system to the body, cause ARDS and multiple organ failure, and finally lead to death in severe cases of SARS-CoV-2 infection, just like what occurs in SARS-CoV and MERS-CoV infection [5] . Patients infected with COVID-19 showed higher leukocyte numbers, abnormal respiratory findings, and increased levels of plasma proinflammatory cytokines. The main pathogenesis of COVID-19 infection as a respiratory system targeting virus was severe pneumonia, RNAaemia, combined with the incidence of ground-glass opacities, and acute cardiac injury [4] . COVID-19 cytokine storm actually refers to the phenomenon caused by SARS-CoV-2 infection and replication, in which the variety of cytokines in body fluids are rapidly produced after viral infections triggering the "suicide attack" of the human immune system (Fig 2) [7] . The direct cause of death from acute COVID-19 is that the SARS-CoV-2 destroy the human immune mechanism and trigger excessive immunity causing cytokine storm. Moreover, cytokine storm damages lungs and multiple organs of the human body like heart, kidney and liver and eventually leading to multiple organ functions exhaustion [8, 9] . Studies have shown that the SARS-CoV-2 enters cells through angiotensin-converting enzyme 2 (ACE2). For this reason, lung tissue has become the main invasion target of the SARS-CoV-2 with high expression of ACE2. After the virus entered the lung, the immune system sent a large number of immune cells to the lung tissue to kill the virus. This formed pneumonia, and the patient showed fever, cough, and difficulty breathing [4] . However, these immune cells cannot locate the virus accurately because they are not recognizing it. They only attack J o u r n a l P r e -p r o o f indiscriminately and recruit more immune cells to kill the virus. Once a cytokine storm is formed, the immune system may not be able to kill the virus, but it will certainly kill a large number of normal cells in the lung, which will seriously damage the function of the lung [1, 2] . The cytokine release syndrome (CRS) seems to affect patients with severe conditions. Since lymphocytopenia is often seen in severe COVID-19 patients, the CRS caused by SARS-CoV-2 virus has to be mediated by leukocytes other than T cells, as in patients receiving CAR-T therapy; a high WBC-count is common, suggesting it, in association with lymphocytopenia, as a differential diagnostic criterion for COVID-19 [10] . One caveat is that MSCs need to be activated by IFNγ to exert their antiinflammatory effects, which may be absent in severely affected patients as T cells are not well activated by SARS-CoV-2 infection. To enhance effectiveness, one could consider employing the "licensing-approach": pretreat MSCs with IFNγ with/without TNF or IL-1 [2] . Such cytokine-licensed MSCs could be more effective in the suppression of hyperactive immune response and promotion of tissue repair, as licensed-MSCs are effective in LPS-induced acute lung damage [11] . Lung damage is a major hurdle to recovery in those severe patients. Through producing various growth factors, MSCs may help repair of the damaged lung tissue. It is important to mention that various studies have shown that in animal models with bleomycin-induced lung injury, vitamin B3 (niacin or nicotinamide) is highly effective in preventing lung tissue damage [12] . At present there is any specific drug or therapy has been proven to be safe and effective for treating COVID-19. There are no Food and Drug Administration (FDA)approved drugs specifically to treat patients with COVID-19. Although reports have appeared in the medical literature and the lay press claiming successful treatment of patients with COVID-19 with a variety of agents, definitive clinical trial data are needed to identify optimal treatments for this disease. The chemical agents previously used to treat SARS and MERS used as potential candidates to treat COVID-19. The number of drugs and combinational therapies were identified by using previously approved drugs that could inhibit clathrin-mediated endocytosis, targeting viral protease, regulating immunity, inhibiting the inflammatory cytokine surge, improving pulmonary function and reducing lung viral loads, as an inhibitor of the host cell serine protease and angiotensin receptor blockers, lower the risk of acute respiratory distress syndrome (ARDS) and death and thereby inhibit viral infection of cells (Table 1) . Also, the treatments of COVID-19 cytokine storm primarily focus on the anti-shock therapy These include drugs targeting interleukin-1 (IL-1), IL-6, IL-18, and interferon-gamma [29] . While randomized trials will be needed to confirm which, if any, of these therapeutics will effectively treat Covid-19-infected patients with cytokine storm syndrome, IL-6 blockade has recently been reported to be in use in China with successful outcomes in some individuals receiving this as part of their treatment [10] . While working to prevent future outbreaks of deadly coronavirus infections with vaccine development and discovering new or re-purposed anti-viral medicines to treat the virus, we must also use all the knowledge at our disposal to treat those patients most at risk of dying including from Covid-19-induced cytokine storms. There are no financial or other interests related to this review that represent a conflict of interest. J o u r n a l P r e -p r o o f Table 1 . Combinational remedies and drugs as potential targets for COVID-19. Thalidomide and Glucocorticoids SARS-CoV-2 Regulating immunity, inhibiting the inflammatory cytokine surge [30] Remdesivir and IFNa2 Improves pulmonary function and reduce lung viral loads [13] Chloroquine and Hydroxychloroquine SARS-CoV-2 Regulating immunomodulatory effects through attenuation of cytokine production and inhibition of autophagy [31] Lopinavir and Ritonavir HIV, MERS-CoV and SARS-CoV-2 inhibitor, inhibits 3CLpro [13] Lopinavir, oseltamivir and ritonavir Targeting viral protease [32] Lopinavir, ritonavir, and interferon beta Slightly reduces viral loads improving pulmonary function [20] Convalescent plasma SARS-CoV-2, Inhibits virus entry to the target cells, suppress viraemia [13] Hydroxychloroquine and Azithromycin SARS-CoV-2 Viral load reduction through inhibition of replication [33] Camostat mesilate Hydroxychloroquine SARS-CoV-2 Inhibitor of the host cell serine protease and angiotensin receptor blockers [34] Darunavir and Umifenovir SARS-CoV-2 Viral load reduction through inhibition of replication [35] Ribavirin and Interferon-α SARS-CoV-2 Lower the risk of acute respiratory distress syndrome (ARDS) and death [36] Hydroxychloroquine and Nitazoxanide SARS-CoV-2 Adjuvant therapy in Covid-19 [37] Fig 1. COVID-19 pathogenesis phases and potential therapeutic targets (modified and adopted from Siddiqi and Mehra, 2020 [38] ). J o u r n a l P r e -p r o o f Emerging coronaviruses: Genome structure, replication, and pathogenesis COVID-19 infection: the perspectives on immune responses Coronavirus disease COVID-19): current status and future perspectives Clinical features of patients infected with 2019 novel coronavirus in Molecular immune pathogenesis and diagnosis of COVID-19 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Cytokine storm intervention in the early stages of COVID-19 pneumonia COVID-19: consider cytokine storm syndromes and immunosuppression Into the eye of the cytokine storm. Microbiol Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)CRS)? Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Recent discovery and development of inhibitors targeting coronaviruses Global virus outbreaks: Interferons as 1st responders Interaction of SARS and MERS Coronaviruses with the antiviral interferon response MERS, SARS and other coronaviruses as causes of pneumonia Repurposing host-based therapeutics to control coronavirus and influenza virus Coronaviruses -drug discovery and therapeutic options Treatment of SARS with human interferons The pathogenesis and treatment of the `Cytokine COVID-19 Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19) SARS-CoV-2: Recent Reports on Antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus Discovering drugs to treat coronavirus disease 2019 (COVID-19) Hydroxychloroquine and nitazoxanide combination therapy for COVID-19 COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal He currently working as Professor, Zhejiang Chinese Medical University, China. Previously worked as associate Professor Received Excellent Youth Talent Project from National Science Fund Also having 17 Chinese patents and 28 research projects as PI and received 14 research awards. His expertise is on biotechnology of plant and food bioactive compounds and their biological evaluation. His research mainly focused on functional food